The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

Journal of Psychopharmacology

Volumn 20, Issue 6, 2006, Pages 834-841

  Van, Linn M ^a   Heydari, Amir ^a   Yang, Jiansong ^b   Hargreaves, Judith ^c   Rowland Yeo, Karen ^b   Lennard, Martin O ^a   Tucker, Geoffrey T ^a,b   Rostami Hodjegan, Amin ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

CYP2D6; Ecstasy; MDMA; Mechanism based enzyme inhibition

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DEXTROMETHORPHAN; DEXTRORPHAN;

ARTICLE; DILUTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION; GENETIC POLYMORPHISM; HUMAN; MOLECULAR PROBE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DATA INTERPRETATION, STATISTICAL; DEXTROMETHORPHAN; DEXTRORPHAN; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HALF-LIFE; HALLUCINOGENS; HUMANS; KINETICS; MICROSOMES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; ORGANISMS, GENETICALLY MODIFIED; SACCHAROMYCES CEREVISIAE; SPECTROMETRY, FLUORESCENCE;

EID: 33750357086     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106062902     Document Type: Article

References (19)

1. Ching M S, Blake C L, Ghabrial H, Ellis S W, Lennard M S, Tucker G T, Smallwood R A (1995) Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharm 50: 833-837
2. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095
3. Delaforge M, Jaouen M, Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP2D. Environmental Toxicology and Pharmacology 7: 153-158
4. de la Torre R, Farre M, Ortuno J, Mas M, Brenneigen R, Roset P N, Segura J, Cami J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109
5. Ellis S W, Ching M S, Watson P F, Henderson C J, Simula A P, Lennard M S, Tucker GT, Woods H F (1992) Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharm 44: 617-620
6. Ghanbari F, Rowland-Yeo K, Bloomer J C, Clarke S E, Lennard M S, Tucker G T, Rostami-Hodjean A (2006) A critical evaluation of the experimental design of studies of mechanism-based inhibition studies and the assessment of their implications for in vitro-in vivo extrapolation. Curr Drug Metab 7: 315-334
7. Heydari A, Rowland Yeo K, Lennard M S, Ellis S W, Tucker G T, Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphethamine Drug Metab Dispos 32: 1213-1217
8. Jacqz-Aigrain E, Menard Y, Popon M, Mathieu H (1989) Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection J Chromatogr 495: 361-363
9. Kreth K P, Kovar K A, Schwab M, Zanger U M (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem Pharm 59: 1563-1571
10. Lin L Y, Di Stefano E W, Schmitz D A, Hsu L, Ellis S W, Lennard M S, Tucker G T, Cho A K (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25: 1059-1064
11. Liston H L, DeVane L, Boulton D W, Risch S C, Markowitz J S, Goldman J (2002) Differential time course of cytochrome P4502D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharm 22: 169-173
12. Lowry O, Rosebrough N, Farr A, Randall R (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-275
13. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: evidence for its hemoprotein nature. J Biol Chem 236: 2370-2378
14. Ramamoorthy Y, Yu A M, Suh N, Haining R L, Tyndale R F, Sellers E M (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine ('ecstasy') metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharm 63: 2111-2119
15. Renwick A B, Watts P S, Edwards R J, Barton P T, Guyonnet I, Price R J, Tredger J M, Pelkonen O, Boobis A R, Lake B G (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28: 1202-1209
16. Rostami-Hodjegan A, Tucker G T (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technology 1: 441-448
17. Silverman R B (1998) Mechanism-based Enzyme Inactivation. In Chemistry and Enzymology. Vol 1. CRC Press Inc., Boca Raton, Florida
18. Tucker G T, Lennard M S, Ellis S W, Woods H F, Cho A K, Lin L Y, Hiratsuka A, Schmitz D A, Chu T Y (1994) The demethylentation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharm 47: 1151-1156
19. Venkatakrishnan K, Obach R S (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33: 845-852